Other Resources

Resources to Broaden Your Knowledge of EGIDs


The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) is dedicated to improving the lives of individuals with eosinophilic gastrointestinal disorders through innovative research, clinical expertise and education via collaborations between scientists, health care providers, patients, and professional organizations. The disorders CEGIR focuses on are eosinophilic esophagitis (EoE),

Eosinophilic gastritis (EG) and eosinophilic colitis (EC). The team has a multidisciplinary approach and integrates expertise in pediatric and adult clinical specialties, including gastroenterology, allergy, immunology and pathology. Funded by the National Institutes of Health (NIH), CEGIR is part of the Rare Diseases Clinical Research Network (RDCRN).

Overall Goals
  • Improve the lives of individuals with eosinophilic gastrointestinal disorders
  • Facilitate research on eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), and eosinophilic colitis (EC) through the development of a Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)
  • Establish a EGID Patient Contact Registry
  • Develop and maintain a website with information for scientists, health care providers, patients, and professional organizations
  • Clinical Research Project 1 Goals
  • Determine the correlation of clinical outcome measures (COMs) and patient-reported outcomes (PROs) with the histological disease activity as measured by mucosal eosinophil counts
  • Develop a new gold standard for EoE, EG, and/or EC diagnosis and monitoring
  • Determine the correlation of the molecular profile for EoE, EG, and EC with COMs and mucosal eosinophilia
  • Clinical Research Project 2 Goals
  • Optimize treatment of EoE with readily available therapies (diet and steroids)
  • Develop a personalized medicine approach based on biomarker analysis that can predict the best treatment for individual patients
  • Evaluate the efficacy of different restricted diets and determine whether patients who experience diet failure remain responsive to swallowed glucocorticoids (SGC) therapy
  • Pilot/Demonstration Clinical Research Program Goals
  • Support new ideas that have potential to create and/or change paradigms concerning EoE, EG, and EC
  • Training (Career Development) Program Goals
  • Train new investigators in clinical and translational research, enhancing the likelihood of academic success for the investigators in training
  • Enable CEGIR Trainees to become independent clinical and/or translational investigators
  • Aid CEGIR Trainees in developing a broad understanding of the basic, translational, and clinical science pertinent to the immunobiology, pathogenesis, and genetics of EoE, EG, and EC via didactic instruction
  • Facilitate CEGIR Trainee networking and integration in the EoE, EG, and EC research community
  • Patient Advocacy Goals

    In collaboration with our partner Patient Advocacy Groups (PAGs):

  • Develop efficient pathways to communicate the latest clinical and research developments to patients and their families (via websites, social media, newsletters, conferences, contact registries)
  • Offer a forum for the collection and dissemination of patient and family perspectives and priorities
  • Offer public educational initiatives to raise awareness of and quality of care for eosinophilic GI diseases
  • Industry Collaboration Goals
  • Partner with industry in order to improve the lives of patients with EGIDs, including conducting clinical trials
  • CURED both supports and is a part of the Consortium of Eosinophilic Gastrointestinal Researchers (CEGIR). CEGIR was founded in Fall 2014 with an NIH grant (U54 AI117804) and is believed to be the first to establish a network focusing on the three distinct diseases of eosinophilic esophagitis, eosinophilic gastritis, and eosinophilic colitis. CEGIR furthers research and clinical expertise, trains clinical investigators, supports pilot clinical research projects, and provides access to information related to eosinophilic disorders for basic and clinical researchers, physicians, patients, and the lay public.

    The grant is funded by the Office of Rare Diseases Research, which is part of the NIH’s National Center for Advance Translational Studies, as part of the Rare Disease Research Network. This award is co-funded by the National Center for Advancing Translational Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute of Allergy and Infectious Diseases. CURED is one of the patient advocacy organizations that contributes meaningfully by leading from within CEGIR and also donates $25 thousand to CEGIR’s initiatives. Coinciding with Rare Disease Day® 2015.



    CEGIR launched a patient contact registry for individuals with eosinophilic gastrointestinal diseases. The registry is located at www.rdcrn.org/CEGIR, and its purpose is to create a single, international database with information submitted by patients and their families. Establishing such a database will enable CEGIR investigators to identify and recruit patients for new research studies directed towards improving treatments and clinical care.

    Outside Resources

    The National Organization for Rare Disorders (NORD)

    The National Organization for Rare Disorders (NORD) is dedicated to helping the nearly 30 million Americans with rare diseases, and the organizations that serve them, through programs of education, advocacy, research, and patient services.



    “The Patient Contact Registry is a critical tool to help advance EGIDs research efforts. CURED is actively involved in the work CEGIR is doing and we are excited to encourage the use of the registry. This is an important and exciting development for the EGID community. Patients and parents want to hear about the research, they want to be asked for their input – they want to be active participants in the research process. This registry offers our patient community the opportunity to have substantially greater visibility to ongoing studies and to have that information placed directly in their inbox. We strongly encourage everyone who has been diagnosed with an EGID to enroll.” – Ellyn Kodroff, President and Founder of CURED